Acadian Asset Management
KYMR icon

Acadian Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Acadian Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
1,035
+556
+116% +$47.8K ﹤0.01% 1730
2026
Q1 		$39K Sell
479
-903
-65% -$71.5K ﹤0.01% 1883
2025
Q4 		$107K Buy
+1,382
New +$93.3K ﹤0.01% 1660
2024
Q4 		– Sell
-2,328
Closed -$110K – 1918
2024
Q3 		$110K Buy
+2,328
New +$103K ﹤0.01% 1562
2021
Q2 		– Sell
-3,004
Closed -$117K – 2113
2021
Q1 		$117K Sell
3,004
-1,975
-40% -$119K ﹤0.01% 1638
2020
Q4 		$309K Buy
+4,979
New +$243K ﹤0.01% 1395

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Acadian Asset Management's KYMR Position: Q2 2026 in Review

Acadian Asset Management increased its Kymera Therapeutics (KYMR) stake by 116% in Q2 2026, buying an estimated $47.8K and bringing the position to 1,035 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

Acadian Asset Management first reported a position in KYMR in Q4 2020 and has held it in 6 quarters since. The position peaked at $309K in Q4 2020. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Acadian Asset Management held 1,035 shares of Kymera Therapeutics worth $118K as of Q2 2026.
  • Acadian Asset Management bought 556 Kymera Therapeutics shares in Q2 2026, an estimated $47.8K.
  • Kymera Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1730 holding.
  • Acadian Asset Management first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • Acadian Asset Management's Kymera Therapeutics position peaked at $309K in Q4 2020.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.